Blue Water Biotech, Inc. (BWV) on Monday announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company, and stated that the combined company will operate under the name Onconetix, Inc (Nasdaq: ONCO).
The acquisition of Proteomedix has been made through an all-stock consideration, which provides Proteomedix shareholders with an initial 19.9% ownership stake in Onconetix.
Furthermore, this acquisition will establish Onconetix with a European headquarters located in Zurich, Switzerland, with two members of Proteomedix who will become executives of Onconetix.
Onconetix's commercial products are FDA-approved Entadfi, which is used for the treatment of benign prostatic hyperplasia (BPH), and a European CE IVD-approved Proclarix, for prostate diagnostics and a lab-developed test (LDT) currently in the U.S., which was originally developed by Proteomedix.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.